| *Sponsored by Nutriband Inc.
(Nasdaq: NTRB) Jumps Green At The Bell Behind Breaking News And Triggered Technicals
October 28th Greetings, Friend!
Nutriband Inc. (Nasdaq: NTRB) is all over our radar Tuesday AM. Here's why...
Breaking news! Check this out:
Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fent--anyl Patch
Nutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENT-A-NYL (abuse deterrent transdermal system) through commercialization.
Nutriband received final meeting minutes from FDA and is incorporating the feedback into the development program as it moves forward to an IND filing in support of a Human Abuse Potential (HAP) clinical study for the product.
ORLANDO, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received final meeting minutes from its recent virtual face-to-face meeting held on September 18, 2025 with the United States Food and Drug Administration (US FDA) for its lead product, AVERSA™ FENT-A-NYL (abuse deterrent fent-a-nyl transdermal system). The meeting was held as a videoconference with the Division of Anesthesiology, Addiction Medicine, and Pain Medicine (DAAP) in the Office of Neuroscience (ON), Center for Drug Evaluation and Research (CDER). The proposed indication is management of pain in o-pioid-tolerant patients, severe enough to require daily, around-the-clock, long-term o-pioid treatment and for which alternate treatment options are inadequate.
The purpose of the meeting was to specifically provide feedback on the Chemistry, Manufacturing, and Controls (CMC) plans for the product from submission of an Investigational New Drug Application (IND) through approval of a 505(b)(2) New Drug Application (NDA).
...
“We are thankful for the opp. to discuss the CMC aspects of our abuse deterrent fent-a-nyl patch with the Agency. We are excited to incorporate the advice and constructive feedback that we received from the FDA into our development program as we move towards an IND filing in support of a Human Abuse Potential clinical study,” said Alan Smith, Ph.D., Chief Operating Officer of Nutriband, Inc. and President of 4P Therapeutics subsidiary of Nutriband.
...
Read the full article here.
With breaking news circulating, NTRB jumped the opening bell on a green streak as several key technical indicators remain triggered.
Remember. NTRB is a low float idea with fewer than 4Mn shares in its float. This means volatility potential could be significant.
Consider (Nasdaq: NTRB) for your watchlist and check out my full report below for more company details. -----
This what I'm ready to report today... First off, this is a low float idea with fewer than 4Mn shares in its float. This means volatility potential could be significantly heightened.
Furthermore, earlier this month, this Nasdaq idea saw an analyst reiterate a major $15 target.
From its closing valuation Monday, that target suggests a potential upside of 100+%.
And just to fan the flames a bit more, this dynamo blazed a jaw-dropping $7.50+ surge in just two days back in January after one of my alerts.
Now, that's not say the same thing will happen again, but it's more than enough reason as to why Nutriband Inc. (Nasdaq: NTRB) is climbing my watchlist this week.
Another reason for NTRB rising my watchlist? Part of its due to its innovative approach to transdermal drug delivery and its potential to revolutionize patient care, particularly in the field of pain management and abuse prevention.
The company's primary focus is on developing a portfolio of transdermal pharmaceutical products, with its flagship product being an abuse-deterrent fent-a-nyl patch incorporating their proprietary AVERSA™ technology.
This technology is designed to prevent abuse, misuse, diversion, and accidental exposure of drugs with high abuse potential, addressing a critical issue in the o-pioid crisis.
Furthermore, the company believes this technology has broad applicability to any therapeutic patch where deterring abuse and accidental misuse by children and pets are valuable attributes. | 
Tidak ada komentar:
Posting Komentar